NIMBL

"Nuclease Immune Mediated Brain and Lupus-like conditions (NIMBL): natural history, pathophysiology, diagnostic and therapeutic modalities with application to other disorders of autoimmunity"

Coordinatore	THE UNIVERSITY OF MANCHESTER    more  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: 441613000000 Fax: 441613000000
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.nimbl.eu/ni/Home
Totale costo	6˙978˙247 €
EC contributo	5˙396˙993 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2009-single-stage
Funding Scheme	CP-FP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-06-01   -   2013-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: 441613000000 Fax: 441613000000	UK (MANCHESTER)	coordinator	1˙379˙436.00
2	UNIVERSITY OF LEEDS  Organization address address: WOODHOUSE LANE city: LEEDS postcode: LS2 9JT contact info Titolo: Mr. Nome: Ben Cognome: Williams Email: send email Telefono: 441133000000 Fax: +44 113 343 4058	UK (LEEDS)	participant	748˙642.00
3	Academisch Medisch Centrum bij de Universiteit van Amsterdam  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Ms. Nome: Sharon Cognome: Rieskin Email: send email Telefono: 3120567539 Fax: 31206915462	NL (AMSTERDAM)	participant	672˙947.00
4	UNIVERSITY OF WASHINGTON  Organization address address: BROOKLYN AVENUE NE 4333 city: SEATTLE WA postcode: 98195 9472 contact info Titolo: Ms. Nome: Lynne Cognome: Chronister Email: send email Telefono: +1 206 543 6633 Fax: +1 206 685 1732	US (SEATTLE WA)	participant	667˙893.00
5	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Ms. Nome: Linda Cognome: Ouwerkerk Email: send email Telefono: 31715269596 Fax: 31715268275	NL (LEIDEN)	participant	620˙162.00
6	FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)  Organization address address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA city: BARCELONA postcode: 8028 contact info Titolo: Mr. Nome: Alexandre Cognome: Puerto Valdivieso Email: send email Telefono: 34934020450 Fax: 34934037114	ES (BARCELONA)	participant	518˙651.40
7	Children's Research Institute (CRI)  Organization address address: Michigan Avenue 111 city: "Washington, DC" postcode: 20010 contact info Titolo: Ms. Nome: Monique Cognome: Foxx Email: send email Telefono: +1 301 565 8483 Fax: +1 301 565 8474	US ("Washington, DC")	participant	357˙444.00
8	FONDAZIONE ISTITUTO NEUROLOGICO CASIMIRO MONDINO  Organization address address: Via Mondino 2 city: PAVIA postcode: 27100 contact info Titolo: Dr. Nome: Andrea Cognome: Marchetti Email: send email Telefono: 390382000000 Fax: 390382000000	IT (PAVIA)	participant	222˙489.00
9	UNIVERSITAT DE BARCELONA  Organization address address: GRAN VIA DE LES CORTS CATALANES 585 city: BARCELONA postcode: 8007 contact info Titolo: Mr. Nome: Xavier Cognome: Gutierrez Email: send email Telefono: 34934035385 Fax: 34934489434	ES (BARCELONA)	participant	209˙328.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Nuclease Immune Mediated Brain and Lupus-like (NIMBL) conditions, comprising Aicardi-Goutieres Syndrome, Retinal Vasculopathy with Cerebral Leukodystrophy and some cases of Systemic Lupus Erythematosus, are devastating genetic disorders resulting in greatly reduced quality of life, high mortality especially in children, and significant risks of recurrence within affected families. NIMBL conditions are rare, but under diagnosed. No effective treatments or cures exist at present. To enable optimum patient care in Europe and worldwide, a better understanding of the natural course of these disorders and their underlying pathological basis is essential. In the NIMBL project, European and U.S. clinical and basic scientists at the forefront of NIMBL-related research have united to develop a translational approach to these problems. A registry of patients will reveal the natural history of the NIMBL diseases, and the efficacy of current treatments. Investigation of patients together with the use of existing and novel cellular and animal models will precisely define their pathogenesis and identify potential drug targets. These same platforms will then be used to test existing and new drug treatments, thus providing unique opportunities to European companies. The NIMBL project will build on very recent discoveries of the cell-intrinsic initiation of autoimmunity that we have described, and which have major implications for our understanding of the discrimination of self from non-self. This new biological paradigm involves cytosolic sensors that detect accumulated, endogenous nucleic acids, and induce the body to mount an immune response against its own cells. Thus, the investigation of NIMBL diseases will not only improve the health and well-being of NIMBL patients and their families, it will also lead to better treatments of much more common autoimmune disorders including lupus.'